Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue to be around $35.5 billion, close to analysts’ estimates. Its non-GAAP profit of $6.02 per share was 14.1% above analysts’ consensus estimates.
Amgen beats Q2 2025 earnings with $9.179B revenue and $6.02 EPS, but shares dip slightly as market reaction remains muted. CEO highlights growth in biosimilars and raised full-year guidance.
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc.
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Amgen’s 11.6% return over the past six months has outpaced the S&P 500 by 7.3%, and its stock price has climbed to $307.50 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the rest of the therapeutics stocks fared in Q1.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
